Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

Table 6 Adverse events in patients treated to disease progression, adverse events in the absence of disease progression, and the overall treated population

Grade ≥ 3 AEs, %	Patients treated to PD		Patients treated to AEs		All treated patients [18]
Grade ≥ 3 AEs, %	nab-P + Gem	Gem	nab-P + Gem	Gem	nab-P + Gem	Gem
Haematologic^a	n = 223	n = 233	n = 91	n = 56	n = 405	n = 388
Neutropenia	39	31	40	27	38	27
Leukopenia	29	18	41	21	31	16
Thrombocytopenia	13	9	14	14	13	9
Anaemia	14	14	19	18	13	12
Febrile neutropenia^b	2	2	4	2	3	1
Nonhaematologic^c	n = 224	n = 233	n = 98	n = 58	n = 421	n = 402
Fatigue	15	5	29	10	17	7
Peripheral neuropathy^d	19	1	21	0	17	1
Diarrhoea	6	2	11	3	6	1

^aBased on laboratory values (some missing values)
^bPercentages were calculated using the n's reported for nonhaematologic AEs
^cBased on investigator assessment of treatment-related events
^dGrouped AE term
AE adverse event, Gem gemcitabine, ITT intent to treat, nab-P nab-paclitaxel, PD progressive disease

ISSN: 1471-2407